EEI-BIOTECHFINANCES Eléments Essentiels d'Information / Essential Elements of Information
Saturday, June 15th 2019 at 11:00am UTC An encouraging 88% of patients on CALQUENCE remained free of disease progression after 12 months, vs. 68% of patients on rituximab combined with idelalisib or bendamustine WILMINGTON, Del.–(BUSINESS WIRE)– AstraZeneca today announced detailed results from the interim analysis of the Phase III ASCEND …
Plus »LOKELMA™ Demonstrated Efficacy in Treating Hyperkalemia in Patients with End-Stage Renal Disease on Hemodialysis
Friday, June 14th 2019 at 11:00am UTC In Phase IIIb DIALIZE trial, 41.2% of LOKELMA patients maintained normal potassium levels pre-dialysis compared to 1% receiving placebo WILMINGTON, Del.–(BUSINESS WIRE)– AstraZeneca today presented positive results from the Phase IIIb DIALIZE trial which investigated the efficacy and safety of LOKELMA (sodium zirconium …
Plus »Baxter Leads Hemodialysis Research Consortium for German Federal Ministry of Education and Research
Friday, June 14th 2019 at 1:00pm UTC Research aimed at improving health-related, quality-of-life outcomes for hemodialysis patients Novel exploration of anticoagulant-free hemodialysis will investigate expanding function of dialysis membranes World-class Baxter research and development team in Hechingen, Germany, to lead consortium DEERFIELD, Ill.–(BUSINESS WIRE)– Baxter International Inc. (NYSE:BAX), a global …
Plus »IMV Inc. to Present at Two Upcoming Investor Conferences
Thursday, June 13th 2019 at 9:08pm UTC DARTMOUTH, Nova Scotia–(BUSINESS WIRE)– IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company, today announced that IMV Chief Executive Officer Frederic Ors will present at the following investor conferences in June: Raymond James Life Sciences and MedTech Conference Date: Wednesday, June …
Plus »Aura Biosciences to Present Interim Phase 1b/2 Clinical Data for AU-011 at the European Society of Ophthalmology 2019 Congress
Friday, June 14th 2019 at 11:00am UTC CAMBRIDGE, Mass.–(BUSINESS WIRE)– Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that interim clinical data from its ongoing Phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, the Company’s lead product candidate …
Plus »Flatiron Health Appoints Cancer Researcher and Pharmaceutical Executive Dr. Michael Vasconcelles as Chief Medical Officer
Friday, June 14th 2019 at 12:00pm UTC Former Unum Therapeutics, Takeda Executive to Advance Flatiron’s Work in the Development of Oncology Real-World Evidence NEW YORK–(BUSINESS WIRE)– Flatiron Health today announced that Dr. Michael Vasconcelles, a practicing oncologist and senior biotechnology and pharmaceutical executive, has joined as Chief Medical Officer, effective …
Plus »IGC to Participate in Arizona’s Industrial Hemp Program
Thursday, June 13th 2019 at 9:32pm UTC BETHESDA, Md.–(BUSINESS WIRE)– India Globalization Capital, Inc. (NYSE: IGC) announces that its subsidiary Holi Hemp’s application has been approved and that it has executed agreements with operators to grow and harvest industrial hemp under the terms and conditions of the Industrial Hemp Program …
Plus »First Human Clinical Trial Results on the Anti-Aging Compound, Urolithin A, PUblished by Amazentis and Researchers From the EPFL and SIB
Friday, June 14th 2019 at 3:00pm UTC Breakthrough translational science of dietary supplementation with Urolithin A, a pomegranate metabolite, on mitochondrial and cellular health in humans published in the journal Nature Metabolism LAUSANNE, Switzerland–(BUSINESS WIRE)– Amazentis, an innovative life sciences company pioneering scientific breakthroughs in nutrition to manage health conditions …
Plus »InVivo Therapeutics Announces Adjournment of Annual Meeting
Friday, June 14th 2019 at 12:00pm UTC – Scheduled to Reconvene on July 2, 2019 – – Company urgently encourages stockholders to vote – CAMBRIDGE, Mass.–(BUSINESS WIRE)– InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) today announced that its 2019 Annual Meeting of Stockholders, scheduled for June 11, 2019, was convened and …
Plus »Shinkowa Pharmaceutical Co., Ltd. Accelerates Comprehensive NMN Activities, All the Way from Establishing In-House Research Laboratory to Commercialization!
Friday, June 14th 2019 at 2:00pm UTC We are the company that will achieve productive aging worldwide with advancing biomedical science. TOKYO–(BUSINESS WIRE)– Shinkowa Pharmaceutical Co., Ltd. (Head office: Chuo Ward, Tokyo, Japan, Representative director: Megumi Tanaka) commercialized the world’s first nutraceuticals and cosmetics containing ?-nicotinamide mononucleotide (NMN), with an …
Plus »
